Central Haemodynamics and Prediction of Cardiovascular Events in Patients With Erectile Dysfunction

Charalambos Vlachopoulos1, Nikolaos Ioakeimidis1, Konstantinos Rokkas1

  • 1Hypertension and Cardiometabolic and Sexual Health Units, First Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece.

Insights

Central hemodynamics, including aortic pressures and augmentation index (AIx), predict major adverse cardiovascular events (MACEs) in men with erectile dysfunction (ED). These findings highlight a potential explanation for the increased cardiovascular risk associated with ED.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Men's Health

Background:

  • Erectile dysfunction (ED) is increasingly recognized as a potential marker for underlying cardiovascular disease (CVD).
  • Traditional risk factors may not fully capture the cardiovascular risk in patients with ED.
  • Central hemodynamics represent a novel area for risk assessment in this population.

Purpose of the Study:

  • To determine if central hemodynamics, specifically aortic pressures and augmentation index (AIx), predict major adverse cardiovascular events (MACEs) in patients with ED.
  • To assess the incremental predictive value of central hemodynamics beyond established cardiovascular risk factors.

Main Methods:

  • A cohort of 398 patients with ED and no prior cardiovascular disease was studied.
  • Central hemodynamics, including aortic systolic pressure, aortic pulse pressure, and augmentation index (AIx), were measured.
  • Major adverse cardiovascular events (MACEs) were tracked over a mean follow-up of 6.5 years.

Main Results:

  • Higher aortic systolic pressure, aortic pulse pressure, and AIx were significantly associated with an increased risk of MACEs.
  • While not significantly improving C-statistic models, AIx and aortic pulse pressure showed improved risk discrimination via integrated discrimination improvement index (IDI).
  • Net reclassification indices indicated marginal to indicative risk reclassification for AIx and aortic pulse pressure.

Conclusions:

  • Elevated central pressures and AIx are independently associated with a higher risk of MACEs in men with ED.
  • These hemodynamic parameters may contribute to explaining the heightened cardiovascular risk observed in patients with ED.
  • Central hemodynamics offer valuable prognostic information in ED patients without established cardiovascular disease.
Abstract

Related Concept Videos

Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
1.0K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
690
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
676
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K